T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Becton Dickinson
BDX
|
+$3.46B |
| 2 |
UnitedHealth
UNH
|
+$2.79B |
| 3 |
Salesforce
CRM
|
+$2.38B |
| 4 |
Sherwin-Williams
SHW
|
+$1.41B |
| 5 |
Philip Morris
PM
|
+$1.34B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$4.44B |
| 2 |
Alphabet (Google) Class C
GOOG
|
+$2.97B |
| 3 |
GE Aerospace
GE
|
+$2.3B |
| 4 |
HCA Healthcare
HCA
|
+$2.17B |
| 5 |
American International
AIG
|
+$1.68B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 26.68% |
| 2 | Healthcare | 19.49% |
| 3 | Consumer Discretionary | 13.07% |
| 4 | Financials | 11.17% |
| 5 | Communication Services | 8.7% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2601
BioXcel Therapeutics
BTAI
$35.2M
| $195K | ﹤0.01% |
922
+50
| +6% | +$10.5K |
|
2602
FuboTV Inc
FUBO
$293M
| $194K | ﹤0.01% |
6,550
+1,156
| +21% | +$53.9K |
|
|
ACR
2603
ACRES Commercial Realty
ACR
$101M
| $191K | ﹤0.01% |
23,265
| – | – |
|
|
LUCK
2604
Lucky Strike Entertainment
LUCK
$941M
| $191K | ﹤0.01% |
18,012
+3,712
| +26% | +$39.5K |
|
2605
eHealth
EHTH
$39.4M
| $190K | ﹤0.01% |
20,335
-4,491
| -18% | -$45.7K |
|
2606
Microvast
MVST
$343M
| $190K | ﹤0.01% |
85,470
+34,270
| +67% | +$147K |
|
2607
Rigel Pharmaceuticals
RIGL
$763M
| $190K | ﹤0.01% |
16,830
+8,520
| +103% | +$171K |
|
2608
BioLife Solutions
BLFS
$1.72B
| $188K | ﹤0.01% |
+13,617
| New | +$200K |
|
|
SELF
2609
Global Self Storage
SELF
$59M
| $188K | ﹤0.01% |
33,399
| – | – |
|
2610
SiriusPoint
SPNT
$2.68B
| $188K | ﹤0.01% |
34,703
+701
| +2% | +$4.21K |
|
|
EPZM
2611
DELISTED
Epizyme, Inc
EPZM
| $188K | ﹤0.01% |
128,228
-12,869
| -9% | -$9.46K |
|
2612
Lightwave Logic
LWLG
$1.18B
| $187K | ﹤0.01% |
28,565
+14,265
| +100% | +$124K |
|
|
SGFY
2613
DELISTED
Signify Health, Inc.
SGFY
| $187K | ﹤0.01% |
13,566
-4,681
| -26% | -$65.9K |
|
2614
Recursion Pharmaceuticals
RXRX
$1.78B
| $186K | ﹤0.01% |
22,800
-539,390
| -96% | -$3.61M |
|
2615
Telos
TLS
$334M
| $186K | ﹤0.01% |
23,040
-1,430
| -6% | -$12.3K |
|
2616
Beam Global
BEEM
$25.8M
| $185K | ﹤0.01% |
11,900
-922
| -7% | -$15.9K |
|
|
TAST
2617
DELISTED
Carrols Restaurant Group, Inc.
TAST
| $185K | ﹤0.01% |
91,690
-2,779
| -3% | -$5.19K |
|
2618
Ecovyst
ECVT
$1.11B
| $183K | ﹤0.01% |
18,586
+647
| +4% | +$6.72K |
|
2619
Aldeyra Therapeutics
ALDX
$91.7M
| $181K | ﹤0.01% |
45,310
-1,054
| -2% | -$3.63K |
|
2620
Butterfly Network
BFLY
$2.47B
| $181K | ﹤0.01% |
58,894
+8,358
| +17% | +$28.9K |
|
2621
Quantum Corp
QMCO
$977M
| $179K | ﹤0.01% |
6,300
+936
| +17% | +$35.4K |
|
2622
Vitamin Cottage Natural Grocers
NGVC
$647M
| $176K | ﹤0.01% |
11,009
| – | – |
|
2623
Immersion
IMMR
$248M
| $175K | ﹤0.01% |
32,800
-12,800
| -28% | -$66.3K |
|
|
CTIC
2624
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
| $173K | ﹤0.01% |
29,039
+1,639
| +6% | +$8.39K |
|
|
AMPS
2625
DELISTED
Altus Power
AMPS
| $172K | ﹤0.01% |
+27,299
| New | +$182K |
|
Similar funds
T. Rowe Price Associates's Q2 2022 Portfolio in Review
As of Q2 2022, T. Rowe Price Associates held 3,063 positions worth $791B, down 20% from $992B the previous quarter. Its ten largest holdings account for 26% of the portfolio.
T. Rowe Price Associates's Q2 2022 filing shows 88 new, 1,490 increased, 1,207 reduced and 101 closed positions. Its largest new stake was ESAB: 6,073,363 shares worth $266M. The largest sale was Meta Platforms (Facebook), an estimated $4.44B.
By sector, the portfolio is most concentrated in Technology at 27% of assets, down from 27% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q2 2022 buy was ESAB: 6,073,363 shares worth $266M.
- T. Rowe Price Associates added most to Becton Dickinson in Q2 2022, an estimated $3.46B increase.
- T. Rowe Price Associates's biggest Q2 2022 reduction was Meta Platforms (Facebook), cutting an estimated $4.44B.
- T. Rowe Price Associates fully exited Ortho Clinical Diagnostics Holdings plc Ordinary Shares in Q2 2022, selling an estimated $364M.
- T. Rowe Price Associates's ten largest holdings make up 26% of its $791B portfolio in Q2 2022.
- T. Rowe Price Associates opened 88 new positions and closed 101 in Q2 2022.
- T. Rowe Price Associates's portfolio value fell 20% quarter-over-quarter to $791B.
Based on T. Rowe Price Associates's 13F filing for Q2 2022, filed 15 Aug 2022.